Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention

Parag K. Shah, Prema Subramanian, Narendran Venkatapathy, Robison Vernon Paul Chan, Michael F. Chiang, John Peter Campbell

Research output: Contribution to journalArticle

Abstract

Background: Aggressive posterior retinopathy of prematurity (APROP), which has a poor visual prognosis, is common in low- and middle-income countries (LMICs) as a result of suboptimal oxygen monitoring (primary prevention). The purpose of this study was to compare outcomes in APROP eyes treated with laser to eyes treated with antivascular endothelial growth factor (anti-VEGF) therapy. Methods: The medical records of a cohort of APROP eyes treated with anti-VEGF (2010-2018) and another of eyes treated with laser photocoagulation (2002-2010) at the same institution in South India were reviewed retrospectively and compared. The main outcome was the proportion of eyes developing retinal detachment during resolution of acute ROP. Results: A total of 398 eyes of 199 preterm babies with APROP were included: 168 eyes were treated with photocoagulation; 230, with anti-VEGF. From 2002 to 2010, compared to the more recent cohort, babies diagnosed with APROP tended to be heavier (P < 0.001), older (P < 0.001), and exposed to fewer days of oxygen (P = 0.02). In the laser-treated cohort, 17 of 168 eyes (10%) developed retinal detachment (7, stage 5; 12, stage 4), compared with 3 of 230 (1%) in the anti-VEGF cohort (all stage 4 [P = 0.002]). Conclusions: The incidence of retinal detachment was significantly lower in eyes treated with anti-VEGF compared with laser-.treated eyes In the absence of a randomized trial, these data suggest that anti-VEGF may lead to better anatomic outcomes, although questions remain concerning dosage, timing, and risks.

Original languageEnglish (US)
JournalJournal of AAPOS
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Tertiary Prevention
Retinopathy of Prematurity
Primary Prevention
Secondary Prevention
Endothelial Growth Factors
India
Lasers
Retinal Detachment
Light Coagulation
Oxygen
Medical Records

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Ophthalmology

Cite this

Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India : implications for primary, secondary, and tertiary prevention. / Shah, Parag K.; Subramanian, Prema; Venkatapathy, Narendran; Chan, Robison Vernon Paul; Chiang, Michael F.; Campbell, John Peter.

In: Journal of AAPOS, 01.01.2019.

Research output: Contribution to journalArticle

@article{69720c355b12445499ee75620842b95f,
title = "Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention",
abstract = "Background: Aggressive posterior retinopathy of prematurity (APROP), which has a poor visual prognosis, is common in low- and middle-income countries (LMICs) as a result of suboptimal oxygen monitoring (primary prevention). The purpose of this study was to compare outcomes in APROP eyes treated with laser to eyes treated with antivascular endothelial growth factor (anti-VEGF) therapy. Methods: The medical records of a cohort of APROP eyes treated with anti-VEGF (2010-2018) and another of eyes treated with laser photocoagulation (2002-2010) at the same institution in South India were reviewed retrospectively and compared. The main outcome was the proportion of eyes developing retinal detachment during resolution of acute ROP. Results: A total of 398 eyes of 199 preterm babies with APROP were included: 168 eyes were treated with photocoagulation; 230, with anti-VEGF. From 2002 to 2010, compared to the more recent cohort, babies diagnosed with APROP tended to be heavier (P < 0.001), older (P < 0.001), and exposed to fewer days of oxygen (P = 0.02). In the laser-treated cohort, 17 of 168 eyes (10{\%}) developed retinal detachment (7, stage 5; 12, stage 4), compared with 3 of 230 (1{\%}) in the anti-VEGF cohort (all stage 4 [P = 0.002]). Conclusions: The incidence of retinal detachment was significantly lower in eyes treated with anti-VEGF compared with laser-.treated eyes In the absence of a randomized trial, these data suggest that anti-VEGF may lead to better anatomic outcomes, although questions remain concerning dosage, timing, and risks.",
author = "Shah, {Parag K.} and Prema Subramanian and Narendran Venkatapathy and Chan, {Robison Vernon Paul} and Chiang, {Michael F.} and Campbell, {John Peter}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jaapos.2019.05.014",
language = "English (US)",
journal = "Journal of AAPOS",
issn = "1091-8531",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India

T2 - implications for primary, secondary, and tertiary prevention

AU - Shah, Parag K.

AU - Subramanian, Prema

AU - Venkatapathy, Narendran

AU - Chan, Robison Vernon Paul

AU - Chiang, Michael F.

AU - Campbell, John Peter

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Aggressive posterior retinopathy of prematurity (APROP), which has a poor visual prognosis, is common in low- and middle-income countries (LMICs) as a result of suboptimal oxygen monitoring (primary prevention). The purpose of this study was to compare outcomes in APROP eyes treated with laser to eyes treated with antivascular endothelial growth factor (anti-VEGF) therapy. Methods: The medical records of a cohort of APROP eyes treated with anti-VEGF (2010-2018) and another of eyes treated with laser photocoagulation (2002-2010) at the same institution in South India were reviewed retrospectively and compared. The main outcome was the proportion of eyes developing retinal detachment during resolution of acute ROP. Results: A total of 398 eyes of 199 preterm babies with APROP were included: 168 eyes were treated with photocoagulation; 230, with anti-VEGF. From 2002 to 2010, compared to the more recent cohort, babies diagnosed with APROP tended to be heavier (P < 0.001), older (P < 0.001), and exposed to fewer days of oxygen (P = 0.02). In the laser-treated cohort, 17 of 168 eyes (10%) developed retinal detachment (7, stage 5; 12, stage 4), compared with 3 of 230 (1%) in the anti-VEGF cohort (all stage 4 [P = 0.002]). Conclusions: The incidence of retinal detachment was significantly lower in eyes treated with anti-VEGF compared with laser-.treated eyes In the absence of a randomized trial, these data suggest that anti-VEGF may lead to better anatomic outcomes, although questions remain concerning dosage, timing, and risks.

AB - Background: Aggressive posterior retinopathy of prematurity (APROP), which has a poor visual prognosis, is common in low- and middle-income countries (LMICs) as a result of suboptimal oxygen monitoring (primary prevention). The purpose of this study was to compare outcomes in APROP eyes treated with laser to eyes treated with antivascular endothelial growth factor (anti-VEGF) therapy. Methods: The medical records of a cohort of APROP eyes treated with anti-VEGF (2010-2018) and another of eyes treated with laser photocoagulation (2002-2010) at the same institution in South India were reviewed retrospectively and compared. The main outcome was the proportion of eyes developing retinal detachment during resolution of acute ROP. Results: A total of 398 eyes of 199 preterm babies with APROP were included: 168 eyes were treated with photocoagulation; 230, with anti-VEGF. From 2002 to 2010, compared to the more recent cohort, babies diagnosed with APROP tended to be heavier (P < 0.001), older (P < 0.001), and exposed to fewer days of oxygen (P = 0.02). In the laser-treated cohort, 17 of 168 eyes (10%) developed retinal detachment (7, stage 5; 12, stage 4), compared with 3 of 230 (1%) in the anti-VEGF cohort (all stage 4 [P = 0.002]). Conclusions: The incidence of retinal detachment was significantly lower in eyes treated with anti-VEGF compared with laser-.treated eyes In the absence of a randomized trial, these data suggest that anti-VEGF may lead to better anatomic outcomes, although questions remain concerning dosage, timing, and risks.

UR - http://www.scopus.com/inward/record.url?scp=85072626627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072626627&partnerID=8YFLogxK

U2 - 10.1016/j.jaapos.2019.05.014

DO - 10.1016/j.jaapos.2019.05.014

M3 - Article

C2 - 31521847

AN - SCOPUS:85072626627

JO - Journal of AAPOS

JF - Journal of AAPOS

SN - 1091-8531

ER -